Pieris Pharmaceuticals, Inc. Forecast, price target & analysts
Pieris Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation
Pieris Pharmaceuticals, Inc. Classifications & Recommendation:
Pieris Pharmaceuticals, Inc. Price Target
| Target Price | $560.00 |
| Price | $15.87 |
| Potential |
3,429.14%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Pieris Pharmaceuticals, Inc. price target 2025.
The average Pieris Pharmaceuticals, Inc. target price is $560.00.
This is
3,429.14%
register free of charge
|
|
| A rating was issued by 3 analysts: 2 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2025 of
3,429.14%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.81 | 6.63 |
| 65.29% | 84.52% | |
| Net Margin | -67.22% | -746.04% |
| 2,830.88% | 1,009.88% |
1 Analyst has issued a sales forecast Pieris Pharmaceuticals, Inc. 2024 . The average Pieris Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | $42.8m | 65.29% |
|---|---|---|
| 2024 |
$6.6m
84.52%
Unlock
|
|
The average Pieris Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2023 | $-28.8m | 4,744.44% |
|---|---|---|
| 2024 |
$-49.4m
71.78%
Unlock
|
|
Net Margin
| 2023 | -67.22% | 2,830.88% |
|---|---|---|
| 2024 |
-746.04%
1,009.88%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -21.80 | -0.50 |
| 4,744.44% | 97.71% | |
| P/E | negative | |
| EV/Sales | negative |
The average Pieris Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2023 | $-21.80 | 4,744.44% |
|---|---|---|
| 2024 |
$-0.50
97.71%
Unlock
|
|
P/E ratio
| Current | -1.26 | 93.85% |
|---|---|---|
| 2024 |
-0.37
70.63%
Unlock
|
|
Based on analysts' sales estimates for 2024, the Pieris Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.22 | 321.82% |
|---|---|---|
| 2024 |
-2.18
278.29%
Unlock
|
|
P/S ratio
| Current | 15.56 | 2,063.33% |
|---|---|---|
| 2024 |
2.73
82.44%
Unlock
|
|
Pieris Pharmaceuticals, Inc....
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
